PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. - Wikidata - wikimedia - TriplyDB

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

http://www.wikidata.org/entity/Q39859169

about

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance Personalized treatment for advanced colorectal cancer: KRAS and beyond Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma Pilocytic astrocytoma: a disease with evolving molecular heterogeneity BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner Decoupling polarization of the Golgi apparatus and GM1 in the plasma membrane A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines PI3K and cancer: lessons, challenges and opportunities Translating genomic profiling to gastrointestinal cancer treatment.Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Caffeic acid derivatives inhibit the growth of colon cancer: involvement of the PI3-K/Akt and AMPK signaling pathways Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.Targeting the cancer kinome through polypharmacology.Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.RAS Interaction with PI3K: More Than Just Another Effector Pathway Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.

P2860

Q21629049-0CB1B687-9074-4FAC-9E14-BD730B9B8E0C Q24318292-5EF5C56C-4AAC-4966-A04D-0F7DF80E9D95 Q26751344-E32D3B99-1004-4360-AD01-5A40A07935A5 Q26781362-C0938D32-3373-41EC-9988-A013609CCD91 Q26795609-D1069808-FA29-49A7-AB0B-828DBFD4B45C Q26822817-B5F98B3E-06C1-4C3E-BB79-815C4FF19735 Q27334924-A132E002-68F2-4083-B20A-3DC67514DCC7 Q27851586-FF9BB395-53FF-4A04-A071-70F3484CD025 Q27851707-62246B5A-EE04-4CA3-9FD3-A80B15A534E0 Q27852623-85A2F8F0-3EC6-4D6B-BC15-8ECCFE5774D3 Q27853310-623F53C0-483D-4869-91ED-5F786A7B06EF Q28076490-F3731CBF-E7F4-4D12-988D-28DDBBA676F8 Q28263921-293B3E4A-D30C-4958-AEC9-E9C46D49DD2C Q28286218-83927E26-1D5E-4C4E-9589-D20348DC1496 Q28481390-C53E1F9F-12CE-4C92-AA94-E6FD2BABF7BE Q28535581-5AC61CE3-37B7-490A-B820-504A0B1DC296 Q28540936-71C7F88F-C0FE-4905-91DD-3058863059D8 Q30080017-E02F58FE-C535-49BD-8626-0730A4345A25 Q30239109-E8D525C4-1046-4555-8BB2-4950D0DC98BB Q30409158-8EC239AA-AC61-42FE-9BFB-805B188A4779 Q33439312-36D74CC2-560B-4DB1-AF0F-0E3BCA64379F Q33564297-FB5185B7-0F99-4D94-B376-83BA7D1CF909 Q33597663-6B13573A-6EE1-4DEB-93B8-D201B43CFFF8 Q33698374-C091790C-6C5F-45AE-9D65-6748087C461A Q33743847-0A5EA001-A939-4AE6-803C-492DE16E929A Q33745140-4CBF9B3B-E20B-494C-9208-6747AD3F1424 Q33793611-916FE0CA-3143-40A0-8EEF-C6B8548986B1 Q33800268-8BF1D0E6-9F10-49CA-BBD4-2B2320EFE95F Q33820374-66DE9854-03BA-4470-9DFF-B6541968905B Q33861173-AC4CE2ED-CD98-487A-8A73-5B9255FA0171 Q33873157-172C561E-8F3A-4FFA-AE2F-390C1869535D Q33893019-EEE12469-2D18-4EF6-A757-A0F5D94926A3 Q33945972-2F3B28A8-5AA7-4B15-9108-1E5FDD4F1B42 Q33955186-69164CB5-32C7-4BC6-A9EE-568E6433E6F7 Q34004748-87134A49-106D-4E6A-8481-ACC29D38D72D Q34097654-31AF4F63-40BD-487F-B7B8-32F0D6A529FF Q34104165-30E842D9-2ADD-41C3-8403-A2F8A396B4BB Q34129528-A8600DCD-28AD-4747-9C84-C6AED76EC8FD Q34202692-214EB34B-8AB3-4AEC-BB2D-F0BA42722BCE Q34223118-ACDFFA1E-6446-4B7A-B1EF-D9EE29CA3287

P2860

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

http://www.wikidata.org/entity/Q39859169

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

@en

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

@nl

type

label

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

@en

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

@nl

prefLabel

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

@en

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

@nl

P1433

Q39859169-1C656172-64C1-40A1-A9D3-7FB4982EEAF3

P1476

Q39859169-E0C70DE2-00D4-4B45-9B96-28DEE7960696

P2093

Q39859169-171D015F-FE48-4A0F-A5DE-528725CAA527

Q39859169-199E81F0-A768-497C-9A89-33B5CC5725D2

Q39859169-4ED8FCA8-EAB4-41D4-A1D4-44DEAFEAB74D

Q39859169-4F86F662-DF5F-4AB0-8050-3AFEFF438F35

Q39859169-694AAEF4-E34D-4EF1-BE76-75F840B6CB9C

Q39859169-7D9E959B-4065-4154-9540-775142057484

Q39859169-97D4FB7D-0228-4F5C-AFBB-622075AA2E21

Q39859169-CEFE9196-C440-46FC-A887-C8556A5A9FFB

Q39859169-F962261A-34AB-4DF0-941D-A0B644FEA748

P304

Q39859169-F733D700-6D7C-41FC-BE58-50443567032E

P31

Q39859169-A07B1C15-42E7-4608-BEE3-9772EE73F340

P356

Q39859169-B0055482-6179-49FE-85F4-C35AEC2BF960

P407

Q39859169-D01BE533-225A-4988-9A68-B9DF024419C6

P433

Q39859169-BB0E0F14-1520-416F-A109-DC7414465C7A

P478

Q39859169-1D4A0422-12F6-423C-AF63-23911468A22C

P577

Q39859169-2B3BE989-8505-4C7E-88B0-F45BCFE63774

P698

Q39859169-4A48DA5A-8242-4A3A-948C-672A2D5195D3

P356

0008-5472.CAN-08-4765

P1433

Cancer Research

P1476

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.

@en

P2093

Alice Loo

http://www.w3.org/2001/XMLSchema#string

Christoph Lengauer

http://www.w3.org/2001/XMLSchema#string

Frank Stegmeier

http://www.w3.org/2001/XMLSchema#string

Kay Xiaoqin Xiang

http://www.w3.org/2001/XMLSchema#string

Marion Dorsch

http://www.w3.org/2001/XMLSchema#string

Susan Wee

http://www.w3.org/2001/XMLSchema#string

William R Sellers

http://www.w3.org/2001/XMLSchema#string

Yung-Mae Yao

http://www.w3.org/2001/XMLSchema#string

Zainab Jagani

http://www.w3.org/2001/XMLSchema#string

P304

4286-4293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-4765

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19401449

http://www.w3.org/2001/XMLSchema#string